Onconova Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 04:05 pm EST
Share
Onconova Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.000057 million compared to USD 0.000057 million a year ago. Net loss was USD 0.004739 million compared to USD 0.005398 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 0.26 a year ago. Diluted loss per share from continuing operations was USD 0.23 compared to USD 0.26 a year ago.
For the nine months, sales was USD 0.00017 million compared to USD 0.00017 million a year ago. Net loss was USD 0.014764 million compared to USD 0.013544 million a year ago. Basic loss per share from continuing operations was USD 0.7 compared to USD 0.65 a year ago. Diluted loss per share from continuing operations was USD 0.7 compared to USD 0.65 a year ago.
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclibâs mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
TRAWS PHARMA, INC. 
